ICU Medical expects full year earnings near top of guidance

ICU Medical expects its full year 2026 earnings before interest, taxes, depreciation, and amortization to reach the high end of its $415 million to $435 million guidance range. Seeking Alpha Markets and Stock Titan both reported that the company reported third quarter 2026 results featuring record infusion growth, improved margins, and debt reduction. [1][8]

Seeking Alpha Markets reported that earnings per share are tracking toward the upper boundary of the $8.60 to $8.90 range. The outlet noted that performance improved as logistics consolidation normalized across the operating units. [1]

ICU Medical is a medical technology company located in San Clemente, California. Its products include intravenous therapy lines, infusion pumps, needle free vascular access tools, and hemodynamic monitoring systems designed to protect healthcare workers and reduce infections. [9]

Operating performance is evaluated through EBITDA, which measures business profitability before accounting for debt, government obligations, or asset depreciation. As FTMQ Business reported earlier, broader financial conditions remain constrained following the Federal Reserve decision to keep the benchmark interest rate between 3-3/4 percent and 4 percent. [10][11]